Telaprevir for the treatment of hepatitis C

Expert Opinion on Pharmacotherapy
Nicole Forestier, Stefan Zeuzem

Abstract

More than 180 million people worldwide are infected with the chronic hepatitis C virus (HCV), a major cause of liver cirrhosis, and its life-threatening complications including liver failure, portal hypertension and hepatocellular carcinoma. For patients infected with HCV genotype 1, the chances of a sustained virologic response (SVR) with the previous standard of care treatment (Peg-IFN-α + ribavirin) are only 40 - 50%. Neither drug targets a specific HCV protein, and treatment is not only compromised by insufficient SVR rates but also associated with several side effects. With a better understanding of the HCV life-cycle, and of the structural features of HCV proteins, several promising direct antiviral drugs (DAAs) have entered clinical development. This review summarizes the clinical development of telaprevir and discusses the possible role of telaprevir in combination with Peg-IFN-α and ribavirin as a new standard treatment against HCV infection, as well as any possible challenges in the future. Triple therapy, with telaprevir in combination with Peg-IFN-α + ribavirin, is the new standard for chronic hepatitis C treatment in genotype 1-infected patients. At present, there are several next-generation DAAs in clinical develo...Continue Reading

References

Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Nov 9, 2004·Advances in Virus Research·Ralf BartenschlagerThomas Pietschmann
May 10, 2007·Nature Reviews. Microbiology·Darius MoradpourCharles M Rice
Sep 20, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nicole ForestierStefan Zeuzem
Mar 11, 2009·Antimicrobial Agents and Chemotherapy·Matthew F McCownIsabel Nájera
May 1, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE1 Study Team
May 1, 2009·The New England Journal of Medicine·Christophe HézodeUNKNOWN PROVE2 Study Team
Sep 15, 2009·Nature Genetics·Vijayaprakash SuppiahJacob George
Apr 9, 2010·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE3 Study Team
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 16, 2011·The New England Journal of Medicine·Kenneth E ShermanUNKNOWN ILLUMINATE Study Team

❮ Previous
Next ❯

Citations

Jun 27, 2013·The Journal of Infectious Diseases·Yves BenhamouMaria Beumont
Sep 29, 2015·Expert Review of Anti-infective Therapy·Nobuhisa AkamatsuNorihiro Kokudo
Sep 28, 2015·Bioorganic & Medicinal Chemistry Letters·Christophe C ParsyDominique Surleraux
Mar 8, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alessio Aghemo, Raffaele De Francesco
Mar 13, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuhiro KamoKazuhiko Nakao
Sep 11, 2012·Current Opinion in Virology·Laurent Chatel-ChaixDaniel Lamarre
May 29, 2015·World Journal of Hepatology·Kerstin HerzerGuido Gerken

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.